Sign up
Pharma Capital

Futura Medical doses first patient in phase III study

Futura Medical PLC's (LON:FUM) finance director and chief operating officer Angela Hildreth speaks to Proactive London as the group announced they'd dosed the first patient in its phase III clinical study of MED2002 - a gel used to treat erectile dysfunction.

Headline data from the trial is expected next year.

MED2002 is being developed as a rapid onset version of pills such as Viagra and Cialis. It works without side-effects such as headaches.

 

View full FUM profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.